Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2006

View Archived Issues

Preclinical and clinical efficacy and safety of MB-06322 in type 2 diabetes

CHIR-258 continues clinical development

BTG to begin U.S. phase II study for Varisolve

Synthetic Blood International signs Mexican letter of intent for Oxycyte trial

Innate Pharma strengthens TLR platform

Bio-Bridge Science reports preclinical findings from oral HIV vaccine

SPA for registrational metastatic melanoma trial of ipilimumab plus chemotherapy

GTI-2040 to be studied in MDS and AML

Cognate Therapeutics changes name to Cognate BioServices

Phase II study of IR-103 in HIV patients cleared for expansion

PharmaFrontiers changes name to Opexa Therapeutics

Positive results reported for Exubera inhaled insulin

Panflu induces immune response in healthy volunteers

Postoperative MAGE-A3 vaccine well tolerated in NSCLC

Cytokinetics and GSK extend research collaboration

Phase I and II studies evaluate AIR inhaled insulin system

Toray granted Japanese license to AC-200

Neurodex NDA review period extended

Oxybate improves fibromyalgia symptoms

Phase II studies reveal nilotinib activity in hematological malignancies

MT-103 active in non-Hodgkin's lymphoma

Clazosentan reduces occurrence of cerebral vasospasm in study

Avastin approved for second-line use in metastatic colorectal cancer

Cognition improvement by novel alpha7 nAChR partial agonist in rats

Recent Janssen and Zambon patents report novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Novel dopamine D3 receptor antagonists for drug dependence emerge from Bioprojet R&D

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...